InterSystems Unveils IntelliCare: A Next-Generation, AI-Powered Electronic Health Record
InterSystems, a creative data technology provider managing over one billion health records globally, today announced the launch of InterSystems IntelliCare, an AI-powered electronic health record (EHR) and healthcare information system designed to fundamentally change the way clinicians, administrators, and patients engage with healthcare technology.
Introduced at HIMSS25, IntelliCare brings next-generation AI capabilities to EHRs, delivering streamlined workflows, reduced administrative burden, enhanced patient interactions, and improved operational efficiency—all while maintaining rigorous human oversight for accuracy and safety. Built on InterSystems industry-proven TrakCare electronic medical record, IntelliCare is designed specifically for healthcare systems undergoing rapid digital transformation and seeking modern, seamlessly connected solutions without the constraints of legacy systems.
“IntelliCare represents the next step in the evolution of EHRs,” said Don Woodlock, head of global healthcare solutions at InterSystems. “By building an EHR solution with AI at its core, we’re helping healthcare providers focus on what matters: More face time with patients and less screen time.”
“AI is a seismic shift in healthcare technology,” said Jusup Halimi, President Director of EMC Healthcare. “With its advanced AI functionality and decades of proven reliability, InterSystems IntelliCare was the obvious choice to provide our hospitals with the most advanced solution available.”
InterSystems IntelliCare will streamline the EHR experience by integrating AI-driven intelligence across clinical, administrative, and financial workflows. Healthcare systems leveraging IntelliCare can benefit from:
- AI-Driven Efficiency. IntelliCare harnesses generative AI to eliminate administrative inefficiencies, allowing clinicians to spend more time interacting with patients instead of navigating complex data entry screens. Its AI Assistant enables natural language commands and automatic patient history summarization.
- Enhanced Patient Engagement. IntelliCare fosters more natural interactions between patients and providers by removing the need for data entry during office visits. With real-time capture and generation of encounter notes powered by ambient listening and AI-driven documentation tools, clinicians can focus on meaningful conversations with their patients instead of being bogged down by note-taking during visits.
- Optimized Healthcare Operations. Designed to support healthcare administrators and IT teams, IntelliCare streamlines workflows, reduces operational inefficiencies, and facilitates interoperability between systems. Using AI to prepopulate the codes required for billing within the end-to-end revenue cycle management solution helps optimize financial operations and reduce errors while accelerating reimbursement cycles.
- A Future-Ready EHR. Unlike legacy systems, IntelliCare is built with interoperability at its core, seamlessly integrating with existing healthcare IT infrastructures. The solution is available for on-premises, cloud, or SaaS deployment, ensuring flexibility for organizations of all sizes.
InterSystems IntelliCare is available now in the Middle East, Oceania, Latin American, and Southeast Asian markets. InterSystems will showcase IntelliCare at HIMSS25, offering attendees a firsthand look at its AI-powered capabilities. For a full schedule of InterSystems HIMSS25 activities or to coordinate a meeting, please visit: www.intersystems.com/himss/#meet-with-us
About InterSystems
InterSystems, a creative data technology provider, delivers a unified foundation for next-generation applications for healthcare, finance, manufacturing, and supply chain customers in more than 80 countries. Our data platforms solve interoperability, speed, and scalability problems for large organizations around the globe to unlock the power of data and allow people to perceive data in imaginative ways. Established in 1978, InterSystems is committed to excellence through its 24×7 support for customers and partners around the world. Privately held and headquartered in Boston, Massachusetts, InterSystems has 38 offices in 28 countries worldwide. For more information, please visit InterSystems.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304321284/en/
Contacts
Zach Keating
PR@InterSystems.com
+1 617-621-0700
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Blind Sailor Takes the Stage at WEF: "HIRO’s CHOICE" Project to Set Sail13.1.2026 05:00:00 CET | Press Release
“Blind Sailor Single-Handed Pacific Crossing Project 2027” is a world-first initiative in which Mitsuhiro Iwamoto, a completely blind Japanese yachtsman (blind sailor) based in San Diego, will attempt a solo, non-stop trans-Pacific crossing in the spring of 2027. Sailing a 28-foot yacht single-handedly, he aims to cross the Pacific Ocean from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making port. Iwamoto will speak about this project at the World Economic Forum Annual Meeting 2026, to be held in January 2026. Project URL: https://hiros-choice.com/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108087321/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific The message he most wishes to convey at the WEF is the power of choice. He lost his sight at the age of sixteen—a moment when he nearly gave up on life itself. Nevertheless, he chose to live. In
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press Release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press Release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press Release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom